Fluconazole pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "fluconazole pharmacology"
Fluconazole Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
Fluconazole is a triazole antifungal agent with excellent oral bioavailability, typically greater than 90%, and similar pharmacokinetics whether given orally or intravenously Lazar1990Brammer1990Côrrea2011. After administration, peak plasma concentrations are reached in about 2 hours . The drug is minimally bound to plasma proteins (about 12%) and has a volume of distribution close to total body water, allowing it to penetrate well into various body fluids and tissues, including cerebrospinal fluid, sputum, saliva, urine, and skin Lazar1990Brammer1990Pacifici2020.
Fluconazole is metabolically stable, with most of the drug (about 80%) excreted unchanged in the urine, making renal clearance the primary route of elimination Lazar1990Brammer1990Pacifici2020. The elimination half-life is approximately 30 hours in adults, but it can be longer in infants due to immature renal function, and shorter in children Lazar1990Brammer1990Pacifici2020+1 MORE. In preterm and term infants, the half-life ranges from 40 to 60 hours, while in older children it is less than 20 hours Pacifici2020Wang2024.
Dose Proportionality, Steady State, and Special Populations
Fluconazole displays linear pharmacokinetics, meaning plasma concentrations increase proportionally with the dose over a wide range (50–400 mg) Lazar1990Brammer1990. Repeated once-daily dosing leads to a 2.5-fold increase in plasma levels, with steady state achieved by day 7 . In critically ill patients, there is significant variability in pharmacokinetics, and standard dosing may not achieve therapeutic targets, especially for infections with higher minimum inhibitory concentrations (MICs) . Higher loading doses or more frequent dosing may be needed in these cases .
Obesity also affects fluconazole pharmacokinetics, increasing both clearance and volume of distribution, particularly in males. This can result in suboptimal drug exposure, so dose adjustments are recommended for obese patients . In infants and children, dosing should be adjusted based on gestational age, postnatal age, and body weight to achieve appropriate drug levels Pacifici2020Wang2024Adamiszak2025.
Drug Interactions and Safety
Fluconazole is generally safe to use with many other drugs, including cimetidine, rifampin, warfarin, oral hypoglycemics, phenytoin, and cyclosporin A, but it can interact with drugs metabolized by CYP3A enzymes, potentially enhancing or inhibiting their effects Lazar1990Pacifici2020. The most common side effects are gastrointestinal (nausea, vomiting, abdominal pain, diarrhea), headache, rash, and, with prolonged high-dose use, alopecia . High doses during pregnancy have been associated with birth defects .
Antifungal Spectrum and Resistance
Fluconazole is effective against many Candida species, as well as other fungi like Blastomyces, Histoplasma, Coccidioides, and dermatophytes Pacifici2020Côrrea2011. However, some species, such as Candida glabrata, may require higher doses or may not respond well to fluconazole due to resistance, especially with increased azole use Matusik2024Pacifici2020. For invasive C. glabrata infections, alternative antifungal agents are recommended .
Clinical Applications and Dosing Considerations
Fluconazole is used for both prophylaxis and treatment of fungal infections in adults, children, and infants Pacifici2020Wang2024Adamiszak2025. In infants, a loading dose followed by maintenance dosing is common, with intervals adjusted for age and renal function Pacifici2020Wang2024. In pediatric hemato-oncologic patients, higher doses may be needed to achieve therapeutic targets, especially for prophylaxis against Candida species with higher MICs . In patients with renal impairment, dosing should be reduced according to renal function Lazar1990Brammer1990.
Conclusion
Fluconazole is a widely used antifungal with predictable pharmacokinetics, high oral bioavailability, and broad tissue distribution. Its elimination is primarily renal, and dosing must be adjusted in special populations such as infants, children, obese patients, and those with renal impairment. Drug interactions are generally manageable, but monitoring is needed with CYP3A substrates. Resistance patterns and MIC values should guide dosing, especially in critically ill or immunocompromised patients.
Sources and full results
Most relevant research papers on this topic
The clinical pharmacology of fluconazole.
Fluconazole has a unique pharmacokinetic profile, with high oral bioavailability and stable metabolism, and can be safely administered with various other drugs.
Pharmacokinetics and tissue penetration of fluconazole in humans.
Fluconazole has a stable pharmacokinetics and tissue penetration, with similar results in both healthy young adults and elderly individuals, but dose modification is needed in patients with renal impairment.
Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants
Fluconazole dosing in Chinese young infants depends on gestational age and postnatal age, with higher doses needed for treating invasive candidiasis.
Fluconazole Dosing for the Prevention of Candida spp. Infections in Hemato-Oncologic Pediatric Patients: Population Pharmacokinetic Modeling and Probability of Target Attainment Simulations
Hemato-oncologic pediatric patients require increased fluconazole doses for Candida spp. prophylaxis to achieve therapeutic efficacy.
976: POPULATION PHARMACOKINETICS OF CEFEPIME IN CRITICALLY ILL CHILDREN
Aggressive dosing of fluconazole is appropriate for patients on CVVHDF with Saccharomyces cerevisiae fungemia, highlighting the need for experienced pharmacology input in complex medical care.
Review of Fluconazole Properties and Analytical Methods for Its Determination
Fluconazole is an effective antifungal for treating various Candida infections, with potential side effects including nausea, vomiting, headache, rash, abdominal pain, diarrhea, and alopecia.
Try another search
history of the development of the theory of relativity
glucagon-like peptide-1 receptor agonist alternatives
How do cultural factors influence consumer purchase intentions in fashion?
nocturnal leg cramps causes and treatments
How does screen time affect academic performance in elementary students?
probiotics administration methods